CN102333769B - 2-吡啶-2-基-吡唑-3(2h)-酮的衍生物、其制备和作为hif激活剂的治疗用途 - Google Patents
2-吡啶-2-基-吡唑-3(2h)-酮的衍生物、其制备和作为hif激活剂的治疗用途 Download PDFInfo
- Publication number
- CN102333769B CN102333769B CN200980157590.6A CN200980157590A CN102333769B CN 102333769 B CN102333769 B CN 102333769B CN 200980157590 A CN200980157590 A CN 200980157590A CN 102333769 B CN102333769 B CN 102333769B
- Authority
- CN
- China
- Prior art keywords
- methyl
- dihydro
- oxo
- pyrazole
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CXFZTRUCHRVGSG-UHFFFAOYSA-N CCN(c1ccccc1)S(c1ccc(N2NC(C)=C(Cc3cnccc3)C2=O)nc1)(=O)=O Chemical compound CCN(c1ccccc1)S(c1ccc(N2NC(C)=C(Cc3cnccc3)C2=O)nc1)(=O)=O CXFZTRUCHRVGSG-UHFFFAOYSA-N 0.000 description 1
- YMCKQWNQPSDJTM-UHFFFAOYSA-N CN(C1CCCC1)S(c(cc1)cnc1N1NC=C(C(CC(OC)=O)c2ccccc2)C1=O)(=O)=O Chemical compound CN(C1CCCC1)S(c(cc1)cnc1N1NC=C(C(CC(OC)=O)c2ccccc2)C1=O)(=O)=O YMCKQWNQPSDJTM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0807474A FR2940651B1 (fr) | 2008-12-29 | 2008-12-29 | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif |
FR0807474 | 2008-12-29 | ||
FR0904092A FR2949466A1 (fr) | 2009-08-28 | 2009-08-28 | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif |
FR0904092 | 2009-08-28 | ||
PCT/FR2009/052691 WO2010076524A2 (fr) | 2008-12-29 | 2009-12-24 | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102333769A CN102333769A (zh) | 2012-01-25 |
CN102333769B true CN102333769B (zh) | 2014-08-27 |
Family
ID=42008610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980157590.6A Expired - Fee Related CN102333769B (zh) | 2008-12-29 | 2009-12-24 | 2-吡啶-2-基-吡唑-3(2h)-酮的衍生物、其制备和作为hif激活剂的治疗用途 |
Country Status (35)
Country | Link |
---|---|
US (1) | US8541455B2 (fr) |
EP (1) | EP2382205B1 (fr) |
JP (1) | JP5734870B2 (fr) |
KR (1) | KR20110099786A (fr) |
CN (1) | CN102333769B (fr) |
AR (1) | AR074915A1 (fr) |
AU (1) | AU2009334569B2 (fr) |
BR (1) | BRPI0924060A8 (fr) |
CA (1) | CA2748411A1 (fr) |
CL (1) | CL2011001496A1 (fr) |
CO (1) | CO6400141A2 (fr) |
CR (1) | CR20110361A (fr) |
CY (1) | CY1115368T1 (fr) |
DK (1) | DK2382205T3 (fr) |
EA (1) | EA019591B1 (fr) |
EC (1) | ECSP11011155A (fr) |
ES (1) | ES2481042T3 (fr) |
HR (1) | HRP20140680T1 (fr) |
IL (1) | IL213789A (fr) |
MA (1) | MA32976B1 (fr) |
MX (1) | MX2011007054A (fr) |
MY (1) | MY179093A (fr) |
NZ (1) | NZ593751A (fr) |
PA (1) | PA8856201A1 (fr) |
PE (1) | PE20120416A1 (fr) |
PL (1) | PL2382205T3 (fr) |
PT (1) | PT2382205E (fr) |
SG (1) | SG172803A1 (fr) |
SI (1) | SI2382205T1 (fr) |
SM (1) | SMT201400097B (fr) |
TN (1) | TN2011000267A1 (fr) |
TW (1) | TWI482763B (fr) |
UY (1) | UY32369A (fr) |
WO (1) | WO2010076524A2 (fr) |
ZA (1) | ZA201104783B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY155244A (en) | 2008-12-29 | 2015-09-30 | Sanofi Sa | Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof |
JP5902671B2 (ja) * | 2011-03-31 | 2016-04-13 | キッセイ薬品工業株式会社 | ベンジルピラゾール誘導体の製造方法およびその製造中間体 |
JP6126078B2 (ja) * | 2012-03-30 | 2017-05-10 | 第一三共株式会社 | 4−アルカノイルアミノ−3−ピラゾロン誘導体 |
ES2660914T3 (es) * | 2013-03-29 | 2018-03-26 | Takeda Pharmaceutical Company Limited | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD |
DE102016223133A1 (de) | 2016-11-23 | 2018-05-24 | Deere & Company | Geschwindigkeitskontrolle einer Erntemaschine |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175176A (en) * | 1990-07-24 | 1992-12-29 | Bayer Aktiengesellschaft | 1-[pyri(mi)dyl-(2)]-hydroxy-pyrazole microbicides |
CN101213189A (zh) * | 2005-04-28 | 2008-07-02 | 拜耳医药保健股份公司 | 4-(吡啶-3-基)-2-(吡啶-2-基)-1,2-二氢-3h-吡唑啉-3-酮衍生物作为用于治疗心血管和血液学疾病的转录因子-脯氨酰-4-羟化酶的特异性抑制剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750088A (en) | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
JP4499721B2 (ja) | 2003-06-30 | 2010-07-07 | ヒフ バイオ,インク. | 化合物、組成物および方法 |
PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
WO2008047198A1 (fr) | 2006-10-16 | 2008-04-24 | Pfizer Products Inc. | Pyrazolyl thiénopyridines thérapeutiques |
DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
RU2009146851A (ru) | 2007-05-18 | 2011-06-27 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом |
-
2009
- 2009-12-24 EP EP09805789.6A patent/EP2382205B1/fr active Active
- 2009-12-24 JP JP2011542886A patent/JP5734870B2/ja not_active Expired - Fee Related
- 2009-12-24 WO PCT/FR2009/052691 patent/WO2010076524A2/fr active Application Filing
- 2009-12-24 PE PE2011001292A patent/PE20120416A1/es not_active Application Discontinuation
- 2009-12-24 MY MYPI2011003012A patent/MY179093A/en unknown
- 2009-12-24 SI SI200930983T patent/SI2382205T1/sl unknown
- 2009-12-24 MX MX2011007054A patent/MX2011007054A/es active IP Right Grant
- 2009-12-24 MA MA34027A patent/MA32976B1/fr unknown
- 2009-12-24 CA CA2748411A patent/CA2748411A1/fr not_active Abandoned
- 2009-12-24 AU AU2009334569A patent/AU2009334569B2/en not_active Ceased
- 2009-12-24 KR KR1020117017676A patent/KR20110099786A/ko not_active Application Discontinuation
- 2009-12-24 PL PL09805789T patent/PL2382205T3/pl unknown
- 2009-12-24 SG SG2011047503A patent/SG172803A1/en unknown
- 2009-12-24 ES ES09805789.6T patent/ES2481042T3/es active Active
- 2009-12-24 PT PT98057896T patent/PT2382205E/pt unknown
- 2009-12-24 NZ NZ593751A patent/NZ593751A/xx not_active IP Right Cessation
- 2009-12-24 DK DK09805789.6T patent/DK2382205T3/da active
- 2009-12-24 CN CN200980157590.6A patent/CN102333769B/zh not_active Expired - Fee Related
- 2009-12-24 EA EA201170899A patent/EA019591B1/ru not_active IP Right Cessation
- 2009-12-24 BR BRPI0924060A patent/BRPI0924060A8/pt not_active IP Right Cessation
- 2009-12-28 AR ARP090105126A patent/AR074915A1/es unknown
- 2009-12-28 TW TW098145336A patent/TWI482763B/zh not_active IP Right Cessation
- 2009-12-29 UY UY0001032369A patent/UY32369A/es not_active Application Discontinuation
- 2009-12-29 PA PA20098856201A patent/PA8856201A1/es unknown
-
2011
- 2011-05-24 TN TN2011000267A patent/TN2011000267A1/fr unknown
- 2011-06-17 CL CL2011001496A patent/CL2011001496A1/es unknown
- 2011-06-22 EC EC2011011155A patent/ECSP11011155A/es unknown
- 2011-06-23 CR CR20110361A patent/CR20110361A/es unknown
- 2011-06-27 IL IL213789A patent/IL213789A/en not_active IP Right Cessation
- 2011-06-28 ZA ZA2011/04783A patent/ZA201104783B/en unknown
- 2011-06-29 US US13/172,305 patent/US8541455B2/en not_active Expired - Fee Related
- 2011-06-29 CO CO11081326A patent/CO6400141A2/es active IP Right Grant
-
2014
- 2014-07-15 HR HRP20140680AT patent/HRP20140680T1/hr unknown
- 2014-07-22 SM SM201400097T patent/SMT201400097B/xx unknown
- 2014-07-23 CY CY20141100553T patent/CY1115368T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175176A (en) * | 1990-07-24 | 1992-12-29 | Bayer Aktiengesellschaft | 1-[pyri(mi)dyl-(2)]-hydroxy-pyrazole microbicides |
CN101213189A (zh) * | 2005-04-28 | 2008-07-02 | 拜耳医药保健股份公司 | 4-(吡啶-3-基)-2-(吡啶-2-基)-1,2-二氢-3h-吡唑啉-3-酮衍生物作为用于治疗心血管和血液学疾病的转录因子-脯氨酰-4-羟化酶的特异性抑制剂 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1355903B1 (fr) | Derives pyrazole contre la surexpression du facteur tgf | |
JP5063351B2 (ja) | ピラゾールキナーゼモジュレーターおよび使用方法 | |
CN102333769B (zh) | 2-吡啶-2-基-吡唑-3(2h)-酮的衍生物、其制备和作为hif激活剂的治疗用途 | |
CN101248048B (zh) | 吡唑基lxr调节剂 | |
CN108727307A (zh) | 化合物及其使用方法 | |
HU227830B1 (hu) | 1,2-Difenil-pirrol-származékok, alkalmazásuk és ilyeneket tartalmazó gyógyászati készítmények | |
CN110099900B (zh) | 针对Smoothened突变株的刺猬通路抑制剂 | |
WO2008046072A2 (fr) | Inducteurs chimiques de la neurogénèse | |
CN1953968B (zh) | 噻唑化合物及其用途 | |
CN102066323A (zh) | 新的雌激素受体配体 | |
TW202005643A (zh) | 激酶抑制劑 | |
EP1363904A1 (fr) | Pyrazoles utilises comme inhibiteurs du tgf | |
CN100434428C (zh) | 呋咱并苯并咪唑类化合物 | |
CN107231802A (zh) | 杂环衍生物及其用途 | |
CN102333776B (zh) | 2-吡啶-2-基-吡唑-3(2h)-酮的衍生物、其制备和治疗用途 | |
CN105980377B (zh) | 作为egfr-t790m激酶抑制剂的取代的嘧啶类化合物 | |
CN103958505A (zh) | 用于治疗趋化因子介导的病理的二取代的3,4-二氨基-3-环丁烯-1,2-二酮化合物 | |
WO2013060179A1 (fr) | Composés d'acyltétrahydro-β-carboline ainsi que leurs dérivés, leurs applications et leurs procédés de préparation | |
CN102803246A (zh) | Hedgehog途径拮抗剂及其治疗应用 | |
CN104080784A (zh) | 用作卵泡刺激素调节剂的苯甲酰胺衍生物 | |
CN102971327A (zh) | 具有多种酪氨酸激酶抑制活性的抗炎化合物以及含有这些化合物的药物组成物 | |
Shen et al. | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors | |
TW202116740A (zh) | 稠環嘧啶氨基化合物、其製備方法、藥物組合物及應用 | |
US20040077687A1 (en) | Thiazolmines and their use as tgf-beta inhibitors | |
WO2013183718A1 (fr) | Procédé de criblage, substance induisant l'instabilité et/ou la stabilité d'une protéine, et évaluation de l'activité d'une protéine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140827 Termination date: 20171224 |
|
CF01 | Termination of patent right due to non-payment of annual fee |